UC-961 (Cirmtuzumab)

cirmtuzumab · Oncternal Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UC-961 (Cirmtuzumab), covering 2025-12-15 to 2025-12-15. Get the full timeline:

Most recent: Clinical Trial Update: Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 [Phase 1]

See pricing